Vedolizumab for Crohn's disease
- PMID:23394379
- DOI: 10.1517/14712598.2013.770835
Vedolizumab for Crohn's disease
Abstract
Introduction: Crohn's disease (CD) is a chronic inflammatory disorder of unknown aetiology. Currently, approved therapies that include prednisone, anti-metabolites and TNF antagonists, are often ineffective and frequently cause adverse effects. As a result, patients with CD can develop serious complications that adversely affect quality of life. Consequently, new treatment options are needed.
Areas covered: This review discusses the potential role of vedolizumab, a humanised monoclonal antibody that selectively blocks lymphocyte trafficking to the gut, for the treatment of CD. All randomised placebo-controlled trials that evaluated vedolizumab for the treatment of CD were reviewed and safety and efficacy data evaluated.
Expert opinion: Vedolizumab is an effective and well-tolerated drug that is an important advance for the treatment of CD.
Similar articles
- Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S.Sands BE, et al.Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21.Gastroenterology. 2014.PMID:24859203Clinical Trial.
- Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.Hagan M, Cross RK.Hagan M, et al.Expert Opin Drug Saf. 2015;14(9):1473-9. doi: 10.1517/14740338.2015.1063612. Epub 2015 Jul 9.Expert Opin Drug Saf. 2015.PMID:26138111Review.
- [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].Schreiber S, Dignass AU, Hartmann H, Kruis W, Rogler G, Siegmund B, Stallmach A, Witte C, Bokemeyer B.Schreiber S, et al.Z Gastroenterol. 2015 Jun;53(6):591-602. doi: 10.1055/s-0034-1399400. Epub 2015 May 27.Z Gastroenterol. 2015.PMID:26016456Review.German.
- Vedolizumab in the treatment of Crohn's disease.Tarabar D, Hirsch A, Rubin DT.Tarabar D, et al.Expert Rev Gastroenterol Hepatol. 2016;10(3):283-90. doi: 10.1586/17474124.2016.1135051. Epub 2016 Jan 25.Expert Rev Gastroenterol Hepatol. 2016.PMID:26810276Review.
- Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.Lam MC, Bressler B.Lam MC, et al.Immunotherapy. 2014;6(9):963-71. doi: 10.2217/imt.14.66.Immunotherapy. 2014.PMID:25341118Clinical Trial.
Cited by
- Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets.Manuc TE, Manuc MM, Diculescu MM.Manuc TE, et al.Clin Exp Gastroenterol. 2016 Mar 15;9:59-70. doi: 10.2147/CEG.S53381. eCollection 2016.Clin Exp Gastroenterol. 2016.PMID:27042137Free PMC article.Review.
- Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients.Cicala M, Gori M, Balestrieri P, Altomare A, Tullio A, Di Cola S, Dejongh S, Graziani MG, Pagnini C, Carotti S, Perrone G, Ribolsi M, Fiorani M, Guarino MPL, Farré R.Cicala M, et al.Int J Mol Sci. 2024 May 27;25(11):5817. doi: 10.3390/ijms25115817.Int J Mol Sci. 2024.PMID:38892004Free PMC article.
- Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis.Lin L, Liu X, Wang D, Zheng C.Lin L, et al.Medicine (Baltimore). 2015 Mar;94(10):e556. doi: 10.1097/MD.0000000000000556.Medicine (Baltimore). 2015.PMID:25761174Free PMC article.Review.
- Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?Gilroy L, Allen PB.Gilroy L, et al.Clin Exp Gastroenterol. 2014 May 22;7:163-72. doi: 10.2147/CEG.S45261. eCollection 2014.Clin Exp Gastroenterol. 2014.PMID:24899819Free PMC article.Review.
- Bedside to bench: defining the immunopathogenesis of psoriatic arthritis.Bravo A, Kavanaugh A.Bravo A, et al.Nat Rev Rheumatol. 2019 Nov;15(11):645-656. doi: 10.1038/s41584-019-0285-8. Epub 2019 Sep 4.Nat Rev Rheumatol. 2019.PMID:31485004Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials